BET Inhibition Is an Effective Approach Against KRAS-driven PDAC and NSCLC

Oncotarget - United States
doi 10.18632/oncotarget.24648
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Targeted Inhibition of Superoxide Dismutase 1 Is Effective in NSCLC

Cancer Discovery
Oncology
2013English

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination With PI3K Inhibition.

Clinical Cancer Research
Cancer ResearchOncology
2018English

KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PD-L1 Is a Direct Target of Cancer-Foxp3 in Pancreatic Ductal Adenocarcinoma (PDAC), and Combined Immunotherapy With Antibodies Against PD-L1 and CCL5 Is Effective in the Treatment of PDAC

Signal Transduction and Targeted Therapy
Cancer ResearchGenetics
2020English

mTORC1 Inhibition Is an Effective Treatment for Sporadic Renal Angiomyolipoma

Kidney International Reports
Nephrology
2018English

Hes1 Plays an Essential Role in Kras-Driven Pancreatic Tumorigenesis

Oncogene
Cancer ResearchGeneticsMolecular Biology
2019English

Erratum: Mechanism of MEK Inhibition Determines Efficacy in Mutant KRAS- Versus BRAF-driven Cancers

Nature
Multidisciplinary
2013English

BET Proteins: An Approach to Future Therapies in Transplantation

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2017English

Simultaneous Bet/Crebbp/Ep300 Targeting Approach Compared to Single Bet or Crebbp/Ep300 Inhibition in Diffuse Large B-Cell Lymphoma (Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy